Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMMU $2.20 0.3800 +20.88%
SCLN $8.76 0.6500 +8.01%
VBLT $3.39 0.2300 +7.28%
PVCT $0.52 0.0298 +6.11%
SNSS $0.79 0.0250 +3.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KITE $41.47 -5.7200 -12.12%
OHRP $3.16 -0.3700 -10.48%
PBYI $39.72 -4.2600 -9.69%
CRIS $1.42 -0.1500 -9.55%
ATRA $17.16 -1.6800 -8.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

(Amgen) Feb 4, 2016 - Amgen today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study.
read corporate press release 



IVF Babies at Higher Risk for Blood Cancer

(U.S. News & World Report/HealthDay News) Feb 4, 2016 - Children born via IVF had a 67 percent increased risk of leukemia and a more than tripled risk of Hodgkin's lymphoma, according to new study in Norway.
read article 



Lab Criticized As Slow To Act In Fatal French Drug Trial

(Reuters) Feb 4, 2016 - An initial inquiry into a clinical drug trial that left one person dead and five others hospitalised in France last month found that the laboratory conducting the tests was slow to react when the first patient fell ill.
read article 



What New Data Tell Us About Doctor Choice

(Wall Street Journal/Washington Wire blog) Feb 4, 2016 - Just 4% of the non-elderly with health coverage say that they are “very dissatisfied” with the choice of doctors in their plan’s network; almost nine in 10 say they are satisfied.
read article (paid subscription required) 



U.S. Panel Green-Lights Creation of Male 3-Person Embryos

(Scientific American/Nature magazine) Feb 3, 2016 - The U.S. Food and Drug Administration (FDA) should approve clinical trials to transfer DNA from healthy human eggs to diseased embryos, the US National Academy of Medicine said today.
read article 



Seven $1 Billion-Plus Drugs Seen Reaching Market in 2016

(Reuters) Feb 3, 2016 - Drug companies are likely to launch seven "blockbuster" drugs in 2016, each with $1 billion-plus annual sales potential, led by new treatments for liver disease and HIV, according to a Thomson Reuters analysis.
read article 



Keep Cancer Alive To Stop It Spreading, Say Scientists

(The Telegraph [UK]) Feb 4, 2016 - Keeping cells alive around a tumour stops it expanding, the University of Cambridge has discovered.
read article 



Meet the Terminal Cancer Patient Who Stumped Hillary Clinton on Death With Dignity at CNN's Town Hall

(Washington Post/Morning Mix blog) Feb 4, 2016 - Compared with buttoned-up debates — podiums, moderators, talking points — town halls give candidates a chance to come off as regular folk. They sit on stools.
read article (free registration required) 



Partnership Brings Together Roswell Park with Buffalo Medical Group

(Buffalo Business First) Feb 4, 2016 - A new partnership with Buffalo Medical Group brings Roswell Park Cancer Institute a step closer to community physicians.
read article 



Stand Up To Cancer Canada Announces New Cancer Stem Cell Dream Team To Attack Brain Cancer in Children and Adults

(AACR) Feb 4, 2016 - A team of top Canadian scientists, including leading pioneers of stem cell research, was named today to lead a new attack on brain cancers in children and adults, using genomic and molecular profiling technologies to focus on the cancer stem cells that drive the growth of tumors.
read press release 



AACR Brings Together Greatest Minds in Cancer Research to Lessen the Global Burden of Cancer

(AACR) Feb 4, 2016 - "On this World Cancer Day, we are proud to join people across the globe in raising public understanding of cancer and the importance of cancer research to conquering cancer and improving public health."
read press release 



Merck: A Leg Up In The Cancer Drug Race

(Wall Street Journal/MoneyBeat blog) Feb 3, 2016 - Highly anticipated results from a phase 3 clinical trial of Keytruda as a single therapy in a form of lung cancer will be available in the middle of the year.
read article (paid subscription required) 



US Oncology Research Translational Oncology Program Enrolls 2,000th Patient in Leading-Edge Phase I Clinical Trials

(The US Oncology Network) Feb 4, 2016 - US Oncology Research, one of the largest community-based oncology research programs in the United States specializing in oncology clinical trials, announced it has recruited its 2,000th patient to participate in a Phase I clinical trial through its Translational Oncology Program (TOP).
read corporate press release 



Blood Simple? Grail’s Cancer Screening Quest Faces Tough Questions

(Xconomy National) Feb 4, 2016 - Three weeks ago the world’s biggest genomic sequencing company, Illumina, unveiled a spinout called Grail to make blood tests that could spot all kinds of cancer in seemingly healthy people, perhaps as soon as 2019.
read article 



Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda

(StreetInsider) Feb 4, 2016 - Seattle Genetics, Inc., today announced that it will receive a one-time $20 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
read article 



FDA Approves Merck's Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)

(Merck) Feb 4, 2016 - First and only intravenous NK1 receptor antagonist approved in the U.S. for use in MEC.
read corporate press release 



Meditation Eases Pain, Anxiety and Fatigue During Breast Cancer Biopsy

(Duke Medicine) Feb 4, 2016 - Meditation eases anxiety, fatigue and pain for women undergoing breast cancer biopsies, according to researchers at the Duke Cancer Institute. They also found that music is effective, but to a lesser extent.
read press release 



Obesity Impact on Generational Cancer Risk 'Needs Study’

(Medscape Medical News) Feb 4, 2016 - More research is needed to unravel the complex relationship between obesity and cancer risk, including the transmission of cancer risk across generations via maternal obesity, argue two experts in a review of the current scientific evidence.
read article (free registration required) 



Investigating Surgery for Women at High Risk of Breast and Ovarian Cancer

(Mayo Clinic) Feb 3, 2016 - In a review article published in the Feb. 4 issue of the New England Journal of Medicine, a pair of Mayo Clinic Cancer Center researchers provide an in-depth look at the issues associated with the care of women in families with hereditary breast and ovarian cancer syndrome who have not yet developed cancer themselves.
read article 



Here's Why ImmunoGen's CEO Is Psyched for Combo Tests With Keytruda

(Boston Business Journal/BioFlash blog) Feb 4, 2016 - ImmunoGen says that in coming months it plans to test its experimental cancer drug in combination with Merck’s drug, Keytruda, after mouse trials done internally at the company — confirmed by academic studies — show the two drugs may multiply each others' effects.
read article 



ASCO Names Advance of the Year: Cancer Immunotherapy

(ASCO) Feb 4, 2016 - At a Capitol Hill briefing today, the American Society of Clinical Oncology (ASCO) announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy – along with almost 60 other important cancer research advances – are described in ASCO’s just-released report, Clinical Cancer Advances 2016: ASCO's Annual Report on Progress Against Cancer.
read press release 



FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)

(Merck) Feb 4, 2016 - First and only intravenous NK1 receptor antagonist approved in the U.S. for use in MEC.
read corporate press release 



ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda(R) (pembrolizumab) for the Treatment of Ovarian Cancer

(ImmunoGen) Feb 4, 2016 - ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy.
read corporate press release 



Pfizer, J&J, Merck Evaluating Technologies For Zika Vaccine

(Reuters) Feb 3, 2016 - Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.
read article 



Cancer Treatment Development To Be Speeded Up By New London Research Hub

(The Guardian/Press Association [UK]) Feb 3, 2016 - New cancer research campus to bring together 10,000 scientists, clinical and support staff and hopes to deliver at least two new drugs every five years.
read article